Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.

Li D, Lee D, Dere RC, Zheng B, Yu SF, Fuh FK, Kozak KR, Chung S, Daniela BY, Nazzal D, Danilenko D, Go MAT, Williams M, Polson AG, Poon KA, Prabhu S.

Br J Pharmacol. 2019 Jul 3. doi: 10.1111/bph.14784. [Epub ahead of print]

PMID:
31270798
2.

Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

Su D, Chen J, Cosino E, Dela Cruz-Chuh J, Davis H, Del Rosario G, Figueroa I, Goon L, He J, Kamath AV, Kaur S, Kozak KR, Lau J, Lee D, Lee MV, Leipold D, Liu L, Liu P, Lu GL, Nelson C, Ng C, Pillow TH, Polakis P, Polson AG, Rowntree RK, Saad O, Safina B, Stagg NJ, Tercel M, Vandlen R, Vollmar BS, Wai J, Wang T, Wei B, Xu K, Xue J, Xu Z, Yan G, Yao H, Yu SF, Zhang D, Zhong F, Dragovich PS.

Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.

PMID:
30966735
3.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG.

Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8.

4.

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.

Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV.

MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2.

5.

An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.

Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, Chiu C, Liang WC, Wu Y, Chalouni C, Sadowsky J, Clark V, Hendricks A, Poon KA, Chu W, Pillow T, Schutten MM, Flygare J, Polson AG.

Clin Cancer Res. 2019 Feb 15;25(4):1358-1368. doi: 10.1158/1078-0432.CCR-18-0333. Epub 2018 Jun 29.

PMID:
29959143
6.

Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC.

Figueroa I, Leipold D, Leong S, Zheng B, Triguero-Carrasco M, Fourie-O'Donohue A, Kozak KR, Xu K, Schutten M, Wang H, Polson AG, Kamath AV.

MAbs. 2018 Jul;10(5):738-750. doi: 10.1080/19420862.2018.1465160. Epub 2018 May 18.

7.

Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.

Zhang D, Yu SF, Khojasteh SC, Ma Y, Pillow TH, Sadowsky JD, Su D, Kozak KR, Xu K, Polson AG, Dragovich PS, Hop CECA.

Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18.

8.

Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.

Dragovich PS, Broccatelli F, Chen J, Fan P, Le H, Mao W, Pillow TH, Polson AG, Wai J, Xu Z, Yao H, Zhang D.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5300-5304. doi: 10.1016/j.bmcl.2017.10.023. Epub 2017 Oct 13.

PMID:
29079474
9.

Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.

Staben LR, Yu SF, Chen J, Yan G, Xu Z, Del Rosario G, Lau JT, Liu L, Guo J, Zheng B, Cruz-Chuh JD, Lee BC, Ohri R, Cai W, Zhou H, Kozak KR, Xu K, Lewis Phillips GD, Lu J, Wai J, Polson AG, Pillow TH.

ACS Med Chem Lett. 2017 Sep 5;8(10):1037-1041. doi: 10.1021/acsmedchemlett.7b00243. eCollection 2017 Oct 12.

10.

Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.

Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, Pillow TH, Sadowsky J, Cheung TK, Phung Q, Haley B, Lee BC, Akita RW, Sliwkowski MX, Polson AG.

Cancer Res. 2017 Dec 15;77(24):7027-7037. doi: 10.1158/0008-5472.CAN-17-2391. Epub 2017 Oct 18.

11.

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.

Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR.

Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21.

12.

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG.

Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.

13.

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.

Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, Schutten M, Flagella K, Polakis P, Polson AG.

Sci Transl Med. 2015 Nov 18;7(314):314ra186. doi: 10.1126/scitranslmed.aac7433.

PMID:
26582901
14.

An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.

Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, Firestein R, Li D, Schutten M, Stagg NJ, Ogasawara A, Koppada N, Roth L, Williams SP, Lee BC, Chalouni C, Peng I, DeVoss J, Tremayne J, Polakis P, Polson AG.

Mol Pharm. 2015 Jun 1;12(6):1717-29. doi: 10.1021/mp5007745. Epub 2015 Apr 23.

PMID:
25853436
15.

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.

Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.

Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.

16.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G.

Leukemia. 2015 Jul;29(7):1578-86. doi: 10.1038/leu.2015.48. Epub 2015 Feb 24.

PMID:
25708834
17.

The cryptophycins as potent payloads for antibody drug conjugates.

Verma VA, Pillow TH, DePalatis L, Li G, Phillips GL, Polson AG, Raab HE, Spencer S, Zheng B.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):864-8. doi: 10.1016/j.bmcl.2014.12.070. Epub 2015 Jan 2.

PMID:
25613677
18.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

19.

FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, Yu SF, McBride J, de Tute R, Rawstron A, Jack AS, Ebens A, Polson AG.

Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17.

20.
21.

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.

Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D.

Sci Transl Med. 2011 Mar 16;3(74):74ra22. doi: 10.1126/scitranslmed.3001620.

22.

Investigational antibody-drug conjugates for hematological malignancies.

Polson AG, Ho WY, Ramakrishnan V.

Expert Opin Investig Drugs. 2011 Jan;20(1):75-85. doi: 10.1517/13543784.2011.539557. Epub 2010 Dec 11. Review.

PMID:
21142808
23.

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A.

Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1.

PMID:
20596033
24.

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.

Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG.

Mol Cancer Ther. 2009 Oct;8(10):2937-46. doi: 10.1158/1535-7163.MCT-09-0369. Epub 2009 Oct 6.

25.

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.

Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG.

Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24.

26.

Toward an effective targeted chemotherapy for multiple myeloma.

Polson AG, Sliwkowski MX.

Clin Cancer Res. 2009 Jun 15;15(12):3906-7. doi: 10.1158/1078-0432.CCR-09-0572. Epub 2009 Jun 9.

27.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

28.

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.

Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C, Hongo JA, Gogineni A, Cole MJ, Vandlen R, Stephan JP, Young J, Chang W, Scales SJ, Ross S, Eaton D, Ebens A.

Blood. 2007 Jul 15;110(2):616-23. Epub 2007 Mar 20.

29.

Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.

Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, Yen L, Tan C, Hongo JA, Koeppen H, Ebens A.

Int Immunol. 2006 Sep;18(9):1363-73. Epub 2006 Jul 18.

PMID:
16849395
30.
31.

Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases.

Polson AG, Huang L, Lukac DM, Blethrow JD, Morgan DO, Burlingame AL, Ganem D.

J Virol. 2001 Apr;75(7):3175-84.

32.
33.

RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase.

Polson AG, Bass BL, Casey JL.

Nature. 1996 Apr 4;380(6573):454-6. Erratum in: Nature 1996 May 23;381(6580):346.

PMID:
8602246
34.
35.
36.
37.

Supplemental Content

Loading ...
Support Center